Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Vaxcyte, Inc. (PCVX)
Company Research
Source: GlobeNewswire
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- PCV Pediatric Indication: VAX-24 Infant Phase 2 Study Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025; Initiation of VAX-31 Infant Phase 2 Study Expected in First Quarter of 2025 Subject to IND Application Clearance by Year-End 2024 -- -- $3.3 Billion in Cash, Cash Equivalents and Investments as of September 30, 2024, Including Net Proceeds of $1.4 Billion from September Public Offering -- SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsGlobeNewswire
- 1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst [Yahoo! Finance]Yahoo! Finance
- We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.MarketBeat
PCVX
Earnings
- 11/5/24 - Beat
PCVX
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- PCVX's page on the SEC website